论文部分内容阅读
为探讨汉防己甲素抑制肝纤维化和改善门脉高动力循环的作用机制 ,分 3组测定肝组织中一氧化氮合酶 (NOS)活性和血清中一氧化氮 (NO) ,观察门静脉血流量 (PVF)、门静脉压力 (PVP)、门静脉阻力 (PVR)及肝脏病理学改变。结果显示 ,钙拮抗剂汉防己甲素显著抑制NOS活性和NO生成 ,明显降低PVP和PVF ,病理切片显示汉防己甲素明显防止肝细胞坏死 ,阻止肝纤维化发展。提示抑制NOS活性和NO生成是汉防己甲素防治肝硬化门脉高压症的主要作用机理。
To investigate the mechanism of tetrandrine in inhibiting hepatic fibrosis and improving portal hyperdynamic circulation, nitric oxide synthase (NOS) activity in liver tissue and serum nitric oxide (NO) were measured in three groups and portal vein blood Flow rate (PVF), portal pressure (PVP), portal vein resistance (PVR) and liver pathology. The results showed that tetrandrine, a calcium antagonist, significantly inhibited NOS activity and NO production, significantly decreased PVP and PVF. Pathological sections showed that tetrandrine prevented hepatocellular necrosis and prevented the development of hepatic fibrosis. Tip inhibition of NOS activity and NO generation is the main mechanism of action of tetrandrine against cirrhosis and portal hypertension.